This inventor holds 1 USPTO granted patent. Top assignee: Amylin Pharmaceuticals, Inc.. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Maria Byrne: Innovator in Diabetes Treatment
Introduction
Maria Byrne is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of diabetes treatment through her innovative research and development. Her work focuses on improving the response of pancreatic beta-cells in individuals with impaired glucose tolerance.
Latest Patents
Maria Byrne holds a patent for a composition aimed at treating impaired glucose tolerance (IGT). The patent, titled "Exendin improves β-cell response in subjects with impaired glucose tolerance," describes a composition that includes a compound binding to a receptor for glucagon-like peptide-1, along with a pharmaceutical carrier. This composition is designed to enhance pancreatic β-cell sensitivity to blood glucose levels in humans suffering from IGT. Additionally, the patent outlines a method for improving insulin secretory responses in these individuals by administering the aforementioned composition.
Career Highlights
Maria Byrne is associated with Amylin Pharmaceuticals, Inc., where she continues to advance her research in diabetes treatment. Her work has garnered attention for its potential to significantly impact the management of glucose levels in patients with IGT.
Collaborations
Throughout her career, Maria has collaborated with notable professionals in her field, including Burkhard Göke and Thomas R. Coolidge. These collaborations have further enriched her research and contributed to the development of innovative solutions for diabetes management.
Conclusion
Maria Byrne's contributions to diabetes treatment through her patent and research are noteworthy. Her innovative approach to improving pancreatic function in individuals with impaired glucose tolerance showcases her dedication to advancing medical science.